These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

738 related articles for article (PubMed ID: 26653534)

  • 1. Non-stoichiometric inhibition in integrated lead finding - a literature review.
    Klumpp M
    Expert Opin Drug Discov; 2016; 11(2):149-62. PubMed ID: 26653534
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Affinity-based screening techniques: their impact and benefit to increase the number of high quality leads.
    Bergsdorf C; Ottl J
    Expert Opin Drug Discov; 2010 Nov; 5(11):1095-107. PubMed ID: 22827747
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Industrial medicinal chemistry insights: neuroscience hit generation at Janssen.
    Tresadern G; Rombouts FJR; Oehlrich D; Macdonald G; Trabanco AA
    Drug Discov Today; 2017 Oct; 22(10):1478-1488. PubMed ID: 28669605
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Novel trends in high-throughput screening.
    Mayr LM; Bojanic D
    Curr Opin Pharmacol; 2009 Oct; 9(5):580-8. PubMed ID: 19775937
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Biophysics: for HTS hit validation, chemical lead optimization, and beyond.
    Genick CC; Wright SK
    Expert Opin Drug Discov; 2017 Sep; 12(9):897-907. PubMed ID: 28658992
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Non-stoichiometric inhibition in biochemical high-throughput screening.
    Coan KE; Ottl J; Klumpp M
    Expert Opin Drug Discov; 2011 Apr; 6(4):405-17. PubMed ID: 22646018
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Applications of Biophysics in High-Throughput Screening Hit Validation.
    Genick CC; Barlier D; Monna D; Brunner R; Bé C; Scheufler C; Ottl J
    J Biomol Screen; 2014 Jun; 19(5):707-14. PubMed ID: 24695619
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Fragment-based approaches to anti-HIV drug discovery: state of the art and future opportunities.
    Huang B; Kang D; Zhan P; Liu X
    Expert Opin Drug Discov; 2015 Dec; 10(12):1271-81. PubMed ID: 26372893
    [TBL] [Abstract][Full Text] [Related]  

  • 9. In silico tools used for compound selection during target-based drug discovery and development.
    Caldwell GW
    Expert Opin Drug Discov; 2015; 10(8):901-23. PubMed ID: 25952011
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Biodiversity of small molecules--a new perspective in screening set selection.
    Petrone PM; Wassermann AM; Lounkine E; Kutchukian P; Simms B; Jenkins J; Selzer P; Glick M
    Drug Discov Today; 2013 Jul; 18(13-14):674-80. PubMed ID: 23454345
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Hit finding: towards 'smarter' approaches.
    Langer T; Hoffmann R; Bryant S; Lesur B
    Curr Opin Pharmacol; 2009 Oct; 9(5):589-93. PubMed ID: 19576852
    [TBL] [Abstract][Full Text] [Related]  

  • 12. An overview of molecular fingerprint similarity search in virtual screening.
    Muegge I; Mukherjee P
    Expert Opin Drug Discov; 2016; 11(2):137-48. PubMed ID: 26558489
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Increasing the delivery of next generation therapeutics from high throughput screening libraries.
    Wigglesworth MJ; Murray DC; Blackett CJ; Kossenjans M; Nissink JW
    Curr Opin Chem Biol; 2015 Jun; 26():104-10. PubMed ID: 25909818
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Open access high throughput drug discovery in the public domain: a Mount Everest in the making.
    Roy A; McDonald PR; Sittampalam S; Chaguturu R
    Curr Pharm Biotechnol; 2010 Nov; 11(7):764-78. PubMed ID: 20809896
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Modern drug discovery technologies: opportunities and challenges in lead discovery.
    Guido RV; Oliva G; Andricopulo AD
    Comb Chem High Throughput Screen; 2011 Dec; 14(10):830-9. PubMed ID: 21843147
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Expansion of chemical space for collaborative lead generation and drug discovery: the European Lead Factory Perspective.
    Karawajczyk A; Giordanetto F; Benningshof J; Hamza D; Kalliokoski T; Pouwer K; Morgentin R; Nelson A; Müller G; Piechot A; Tzalis D
    Drug Discov Today; 2015 Nov; 20(11):1310-6. PubMed ID: 26429298
    [TBL] [Abstract][Full Text] [Related]  

  • 17. How to Triage PAINS-Full Research.
    Dahlin JL; Walters MA
    Assay Drug Dev Technol; 2016 Apr; 14(3):168-74. PubMed ID: 26496388
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Active-learning strategies in computer-assisted drug discovery.
    Reker D; Schneider G
    Drug Discov Today; 2015 Apr; 20(4):458-65. PubMed ID: 25499665
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Profile-QSAR: a novel meta-QSAR method that combines activities across the kinase family to accurately predict affinity, selectivity, and cellular activity.
    Martin E; Mukherjee P; Sullivan D; Jansen J
    J Chem Inf Model; 2011 Aug; 51(8):1942-56. PubMed ID: 21667971
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Scopy: an integrated negative design python library for desirable HTS/VS database design.
    Yang ZY; Yang ZJ; Lu AP; Hou TJ; Cao DS
    Brief Bioinform; 2021 May; 22(3):. PubMed ID: 32892221
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 37.